SCIENTIFIC PUBLICATIONS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - SOUTH SAN FRANCISCO, Calif., March 15, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:...
Sutro Biopharma, Inc. Conference Call – Presentation
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel...
15th Annual World ADC London 2025 – Presentation
43rd Annual J.P. Morgan Healthcare Conference – Presentation
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., January 7, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Jefferies London Healthcare Conference – Presentation
15th Annual World ADC Conference – Presentations
Development of Dual-Payload Antibody Drug Conjugates Presenter: Daniel Calarese, Ph.D.Clinical Update & Learnings for Luvelta Targeting Folate Receptor Presenter: Hans-Peter Gerber, Ph.D.Preclinical Safety & Activity of STRO-004, a Tissue Factor ADC Presenter:...
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., November 4, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five...